Toxicities of Pembrolizumab in Cancer Patients
DOI:
https://doi.org/10.54097/hset.v6i.972Keywords:
Pembrolizumab, Keytruda, Toxicities, Cancer.Abstract
Pembrolizumab is a humanized anti-PD1 monoclonal antibody that has been approved for immunotherapy of malignant melanoma, classical hodgkin lymphoma, non-small cell lung cancer, etc. However, the toxicity of pembrolizumab has been demonstrated in preclinical and clinical studies. The main side effects of pembrolizumab are related to the activation of various immune cells in the body. The triggered immune system may attack healthy organs, such as the livers, lungs and kidneys. The resulting toxic reactions can cause varying degrees of damage to the patient's body and need to be taken seriously. In response to the toxic side effects of pembrolizumab, discontinuation of the drug is often taken in conjunction with symptomatic treatment, and the herb is a potentially effective drug in many related diseases. In general, the side effects of immune checkpoint inhibitors are relatively minor and serious toxicities are rare, but some of the serious toxicities are fatal. Therefore, early detection and treatment of adverse reactions are of great interest, and mechanisms as well as treatments of toxicity of pembrolizumab requires further studies.
Downloads
References
J. McLachlan, Immune checkpoint inhibitors and their side effects. Pathology. 2018, Vol.51, pp.S17-S17. DOI: https://doi.org/10.1016/j.pathol.2018.12.036
K. Shih, H.T. Arkenau, J.R. Infante, Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies. Drugs, 2014, vol.74. DOI: https://doi.org/10.1007/s40265-014-0305-6
[3] L. Khoja, M. O. Butler, S. P.Kang, S. Ebbinghaus, A. M. Joshua, Pembrolizumab. Journal for immunotherapy of cancer, 2015, Vol. 3 (1), e 416-946-4501. DOI: https://doi.org/10.1186/s40425-015-0078-9
V. Naranbhai, M. Viard, M. Dean, S. Groha, D. A. Braun, et al. HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. The Lancet. Oncology, 2022, Vol. 23(1), pp.172–184. DOI: https://doi.org/10.1016/S1470-2045(21)00582-9
I. Faisal, M. Masab, S. Gupta, W. Ullah, New drugs and new toxicities: pembrolizumab-induced myocarditis, BMJ case reports, 2018, Vol.2018, p.bcr-2017-223252. DOI: http://dx.doi.org/10.1136/bcr-2017-223252
H. Izzedine, A. Mathian, S. Champiat, C. Picard, C. Mateus, E. Routier, A. Varga, D. Malka, A. Leary, J. Michels, J. M. Michot, A. Marabelle, O. Lambotte, Z. Amoura, J. C. Soria, S. Kaaki, N. Quellard, J. M Goujon, I. Brocheriou, 2019). Renal toxicities associated with pembrolizumab. Clinical kidney journal, 2019, Vol.12(1), pp.81–88. DOI: https://doi.org/10.1093/ckj/sfy100
A. Marjanska, P. Galazka, M. Marjanski. M., Wysocki, J. Styczynski, Efficacy and Toxicity of Pembrolizumab in Pediatric Metastatic Recurrent Melanoma. Anticancer Research, 2019, Vol. 39 (7), pp.3945-3947. DOI: https://doi.org/10.21873/anticanres.13547
B. Calderon, et al. Pembrolizumab Treatment-Induced Liver Toxicity. Case Reports in Gastroenterology, no. 2, 2021, pp. 742–50. DOI: https://doi.org/10.1159/000518128
D. Singh, et al. Drug-Induced Liver Toxicity and Prevention by Herbal Antioxidants: An Overview, Frontiers in Physiology, 2016, pp. 363, DOI: https://doi.org/10.3389/fphys.2015.00363
Z. Wu, et al. Acute Liver Failure Caused by Pembrolizumab in a Patient with Pulmonary Metastatic Liver Cancer. Medicine, no. 51, 2017, pp. e9431. DOI: https://doi.org/10.1097/md.0000000000009431
Eleonora. De Martin, et al. Liver Toxicity as a Limiting Factor to the Increasing Use of Immune Checkpoint Inhibitors, JHEP Reports, no. 6, 2020, pp. 100170. DOI: https://doi.org/10.1016/j.jhepr.2020.100170
W. D. Dumoulin, et al. Renal Toxicity from Pemetrexed and Pembrolizumab in the Era of Combination Therapy in Patients with Metastatic Nonsquamous Cell NSCLC. Journal of Thoracic Oncology, 2020, pp. 1472–83. DOI: https://doi.org/10.1016/j.jtho.2020.04.021
R. Raghavan, and E. Garabed. Acute Interstitial Nephritis a Reappraisal and Update, Clinical Nephrology, no. 3, Dustri-Verlag Dr. Karl Feistle, 2014, pp. 149–62. DOI: https://doi.org/10.5414/cn108386
B. Sprangers. Pembrolizumab-Related Renal Toxicities: Diagnosis First, Treatment Later. Clinical Kidney Journal, no. 1, 2018, pp. 78–80. DOI: https://doi.org/10.1093/ckj/sfy114
H. Izzedine, A. Mathian, S. Champiat, C. Picard, C. Mateus, et. al. Renal toxicities associated with pembrolizumab, Clinical kidney journal, 12(1), 2018, pp. 81–88. DOI: https://doi.org/10.1093/ckj/sfy100
L. Spain, S. Diem, and J. Larkin. Management of toxicities of immune checkpoint inhibitors, Cancer Treatment Reviews, 2016, pp. 51-60, ISSN 0305-7372. DOI: https://doi.org/10.1016/j.ctrv.2016.02.001
P. Cui, J. Ma, F. Wang, et al., Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis, in: Proceedings of the Therapeutics and Clinical Risk Management, 2017, pp. 1259-1271. DOI: https://doi.org/10.2147/TCRM.S143939
A. Majdi, M. Mohammed. S. Ibrahim, et al., Pembrolizumab reactivates pulmonary granulomatosis, in: Proceedings of the Respiratory medicine case reports, 2017, pp. 126–129. DOI: https://doi.org/10.1016/j.rmcr.2017.07.010
C. Jonathan; Q. Christiane; B. William J; R. Naveen, et al., Pembrolizumab-associated sarcoidosis, in: Proceedings of the JAAD Case Reports, 2016, pp. 290-3. DOI: https://doi.org/10.1016/j.jdcr.2016.06.004
L. Vincent; T. Carole; F. Jean-Baptiste; S. Arnaud, et al., Pembrolizumab-induced pneumonitis, in: Proceedings of the ERJ open research, 2017, pp. 00081-2016. DOI: https://doi.org/10.1183/23120541.00081-2016
F. Paraskevi; S. Maria; T. Maria; K. Christina, et al., A Case of Organizing Pneumonia (OP) Associated with Pembrolizumab, in: Proceedings of the Drug Target Insights, 2016:10, pp. 9-12. DOI: https://doi.org/10.4137/DTI.S31565
JJX. Lee, A. Chan, T. Tang, Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin’s lymphoma, in: Proceedings of the Acta Oncologica, 2016, pp. 519-520. DOI: https://doi.org/0.3109/0284186X.2015.1125017
T. Ogawa, J. Miyata, J. Maehara, et al., Fatal airway inflammation induced by pembrolizumab in a patient with NSCLC, in: Proceedings of the Journal of Thoracic Oncology, 2019, pp. e9-e10. DOI: https://doi.org/10.1016/j.jtho.2018.09.002
T. Sugano, M. Seike, R. Noro, et al., A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab, in: Proceedings of the Oncotargets and Therapy, 2018, pp. 5879-5883. DOI: https://doi.org/10.2147/OTT.S169321
O. Abdel-Rahman, H. Oweira, U. Petrausch, D. Helbling, et al., Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review, in: Proceedings of the Expert Review of Anticancer Therapy, 2017, pp. 387-394, DOI: https://doi.org/10.1080/14737140.2017.1296765
S. Feng, J. Coward, E. McCaffrey, J. Coucher, et al., Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors, in: Proceedings of the Journal of Thoracic Oncology, 2017, pp. 1626-1635, DOI: https://doi.org/10.1016/j.jtho.2017.08.007.
E.M. Presotto, G. Rastrelli, I. Desideri, et al., Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study, in: Proceedings of the Journal of endocrinological investigation, 2020, pp. 337–345. DOI: https://doi.org/10.1007/s40618-019-01112-8
K.L. March, M.J. Samarin, A. Sodhi, R.E. Owens, Pembrolizumab-induced myasthenia gravis: A fatal case report, in: Proceedings of the Journal of Oncology Pharmacy Practice, 2018, pp. 146–149. DOI: https://doi.org/10.1177/1078155216687389
B. Sara, G.T. Christie , R.L. Victor, S.T. Kim , N.T. Sonali, A case of acquired generalized lipodystrophy associated with pembrolizumab in a patient with metastatic malignant melanoma, in: Proceedings of the AACE clinical case reports, 2020, pp. e40-e45. DOI: https://doi.org/10.4158/accr-2019-0234
K. Yamamoto, K. Tokumasu, K. Oka, K. Hasegawa , F. Otsuka, Isolated adrenocorticotropin deficiency induced by pembrolizumab for hypopharyngeal cancer: A case report, in: Proceedings of the Clinical case reports, 2021, pp. e04305-e04305. DOI: https://doi.org/10.1002/ccr3.4305
M.L. Vickers, B. Seidl, K. Bigby, B. Chern, et al., Inflammatory Myeloradiculitis Secondary to Pembrolizumab: A Case Report and Literature Review, in: Proceedings of the Case reports in oncological medicine, 2020, pp. 8819296-8819296. DOI: https://doi.org/10.1155/2020/8819296
A. Dinesh, P.J. Krishna, R. Rahul, M. Fade, Pembrolizumab-Induced Pancytopenia: A Case Report, in: Proceedings of the The Permanente journal, 2017, pp. 17-004. DOI: https://doi.org/10.7812/tpp/17-004
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
